Shanghai RAAS Blood Products Co Ltd
SZSE:002252

Watchlist Manager
Shanghai RAAS Blood Products Co Ltd Logo
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Watchlist
Price: 6.89 CNY -0.86% Market Closed
Market Cap: 45.7B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+3%
Revenue
Forecast
+1%
Operating Income
Forecast
+17%
Net Income
Forecast
+21%

Wall Street
Price Targets

Price Targets Summary
Shanghai RAAS Blood Products Co Ltd

Wall Street analysts forecast Shanghai RAAS Blood Products Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Shanghai RAAS Blood Products Co Ltd is 7.55 CNY with a low forecast of 6.87 CNY and a high forecast of 8.4 CNY.

Lowest Forecast
Wall Street Target
6.87 CNY
0% Downside
Average Forecast
Wall Street Target
7.55 CNY
10% Upside
Highest Forecast
Wall Street Target
8.4 CNY
22% Upside
Lowest
Price Target
6.87 CNY
0% Downside
Average
Price Target
7.55 CNY
10% Upside
Highest
Price Target
8.4 CNY
22% Upside
Shanghai RAAS Blood Products Co Ltd Competitors:
Price Targets
ALT
Altimmune Inc
222% Upside
ARGX
argenx SE
38% Upside
SIGHT
Gensight Biologics SA
71% Upside
BSLN
Basilea Pharmaceutica AG
75% Upside
ALT
Altimmune Inc
222% Upside
ARGX
argenx SE
38% Upside
SIGHT
Gensight Biologics SA
71% Upside
BSLN
Basilea Pharmaceutica AG
75% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
4% Downside
NGNE
Neurogene Inc
116% Upside
MRNA
Moderna Inc
79% Upside
MRUS
Merus NV
67% Upside

Revenue
Forecast

Revenue Estimate
Shanghai RAAS Blood Products Co Ltd

For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's revenue is 17%. The projected CAGR for the next 2 years is 9%.

17%
Past Growth
9%
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Shanghai RAAS Blood Products Co Ltd

For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's operating income is 9%. The projected CAGR for the next 3 years is 13%.

9%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Shanghai RAAS Blood Products Co Ltd

For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's net income is 4%. The projected CAGR for the next 2 years is 16%.

4%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-22%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Shanghai RAAS Blood Products Co Ltd's stock price target?
Price Target
7.55 CNY

According to Wall Street analysts, the average 1-year price target for Shanghai RAAS Blood Products Co Ltd is 7.55 CNY with a low forecast of 6.87 CNY and a high forecast of 8.4 CNY.

What is Shanghai RAAS Blood Products Co Ltd's Revenue forecast?
Projected CAGR
9%

For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's revenue is 17%. The projected CAGR for the next 2 years is 9%.

What is Shanghai RAAS Blood Products Co Ltd's Operating Income forecast?
Projected CAGR
13%

For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's operating income is 9%. The projected CAGR for the next 3 years is 13%.

What is Shanghai RAAS Blood Products Co Ltd's Net Income forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's net income is 4%. The projected CAGR for the next 2 years is 16%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 261,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.